呼吸道联检试剂在HIV/AIDS合并呼吸道非典型病原体感染诊断中的应用研究

Diagnostic value of PNEUMOSLIDE IgM in detecting atypical pathogens in HIV/AIDS patients combined with respiratory tract infections

目的探讨呼吸道联检试剂对HIV/AIDS合并呼吸道感染患者的血清样品非典型病原体的诊断价值。方法采用西班牙Vircell公司生产的呼吸道联检试剂(间接免疫荧光法)对419例HIV/AIDS合并呼吸道感染患者进行9种病原体检测。结果 419例中,非典型病原体总阳性率为26.0%,其中嗜肺军团菌1型阳性率居第一位(17.4%),肺炎支原体阳性率居第二位(9.5%),2种及以上病原体混合感染阳性率为10.3%。结论呼吸道联检试剂对于HIV/AIDS合并呼吸道感染患者的病原学诊断有着重要的临床指导意义。

Objective To investigate the diagnostic value of PNEUMOSLIDE IgM in detecting atypical pathogens in serum samples of HIV/AIDS patients combined with respiratory tract infections. Method Nine pathogens were detected by PNEU- MOSLIDE IgM of Vircell, S.L. in 419 HIV/AIDS patients combined with respiratory tract infections by using indirect fluorescent an- tibody technique. Results Atypical pathogen infections were found in 26.0% of 419 HIV/AIDS patients, among which Legionella pneumophila serotype 1 infection accounted for the largest proportion （17.4%） and Mycoplasma pneumonia infection the second （9.5%）. Infections with two or more than two pathogens were found in 10.3% of all the patients. Conclusion PNEUMOSLIDE IgM has an important clinical significance in diagnosis of the pathogens in HIV/AIDS patients combined with respiratory tract infections.